logo-loader

Todos Medical launches web invitation for Long COVID clinical study and offers further patient case study

Published: 09:28 20 Apr 2022 EDT

man working ill in bed
The case study comes from Dr. Lee Morgentaler and concerns a 33-year-old man in top physical shape who presented with COVID-19 like symptoms of fatigue and short term memory loss in mid-March 2020

Todos Medical Ltd. (OTCQB:TOMDF) said it has launched a website for physicians and pediatricians to opt for their patients to take part in a Long COVID clinical study of its supplement product Tollovid and offered a further case study of its potential benefits to one man.

"We believe the societal impact we are seeing with Long COVID is just the tip of the iceberg, with direct impacts on GDP and workforce participation, which is why we cannot sit idly by and do nothing for this massive patient population when we believe clinical research into our 3CL protease inhibitor products is the right path forward," said Gerald Commissiong, the CEO of Todos Medical in a statement.

The company's Tollovid supplement is made from natural ingredients that help maintain healthy immune function and also has potent 3CL protease inhibition properties based upon in vitro functional assays that show strong inhibition of 3CL protease activity.

READ: Todos Medical says Tollovid receives LGC Group’s Informed Sport Certification as it targets athlete support 

The case study comes from Dr. Lee Morgentaler and concerns a 33-year-old man in top physical shape who presented with COVID-19 like symptoms of fatigue and short term memory loss in mid-March 2020.

He had been able to run three miles in 20 minutes, bench press 225 pounds, dead lift 415 pounds, and squat 300 pounds. He worked out at least five days a week and went hiking, reported Todos.

Despite fatigue, dizziness, and loss of short-term memory, he returned to work as a private fitness trainer in June 2020 but could only do two sessions a week due to chest pains from exertion.

He received a first Pfizer vaccine shot on April 14, 2021 without any side effects beyond his baseline status. On May 5, 2021, he received his second Pfizer shot and three weeks later, was hospitalized for chest pain and inability to breath.

"Once in the hospital, tests were done on his EKG and blood and consistent with his baseline before contracting his first case of COVID-19. The hospital did not administer a COVID-19 test. His symptoms after the three-day hospital stay were fatigue, dizziness, and memory loss," said Todos.

In October 2021, the patient believed he contracted the Delta variant. His wife tested COVID-19 positive and he had symptoms of vomiting, diarrhea, coughing, worse fatigue, joint pain, and erectile dysfunction.

The patient started a regimen of Tollovid Daily on February 14, 2022. He took two Tollovid Daily capsules for 30 days and his symptoms completely resolved in three days.

"After three days of treatment, his fatigue subsided, his memory improved, the joint pain dissipated, and his erectile dysfunction was resolved. He returned to his baseline routine of working out five times a week and taking his 2-year-old dog for walks. He is no longer treating himself for any Long COVID symptoms," noted Todos.

The company said that the study showed that even a small dose of Tollovid Daily could be used to treat Long COVID but conceded that a "major weakness" of the study is the absence of a PCR positive COVID-19 test.

"The interesting part of this case study is related to the apparent vaccine injury that the patient suffered through. It has been documented in journal articles that a vaccine given during active COVID-19 infection could result in more severe disease.

"The presence of Long COVID, followed by the second vaccination seems to support the theory that some cases of Long COVID are due to viral persistence," suggested Todos.

The link to the website for physicians to indicate their interest in participating in the study is HERE:

Contact the writer at giles@proactiveinvestors.com

ARway.ai announces multiple new SaaS developer contracts in both the United...

ARway.ai (CSE:ARWY, OTCQB:ARWYF) Chief Executive Officer Evan Gappelberg joined Steve Darling from Proactive to announce multiple new SaaS developer sign-ups for its augmented reality experience platform, focusing on AR indoor navigation. These partnerships represent significant milestones in...

1 hour, 42 minutes ago